Introduction
============

Advances in cancer research over the last decade have led to a drive towards personalized medicine. This has been largely facilitated by the identification of tumor-specific biomarkers and advances in the methods used to detect them \[[@b1-crt-2014-362],[@b2-crt-2014-362]\]. Lung cancer is an ideal model of how biomarkers have been identified and used in targeted therapy for specific patient subgroups who harbor the biomarker.

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers, and patients are usually diagnosed in the advanced stages of disease \[[@b3-crt-2014-362]\]. A number of genetic alterations have been identified in patients with NSCLC, and the prevalence of these alterations differs depending on the patient's clinicopathologic features, including ethnicity, gender, smoking history, and histological subtype \[[@b4-crt-2014-362]\]. Mutation of the key tyrosine kinase gene epidermal growth factor receptor (EGFR), involved in growth factor receptor signaling, is commonly observed in tumor samples from patients with NSCLC \[[@b1-crt-2014-362],[@b4-crt-2014-362]\]. A number of small molecule tyrosine kinase inhibitors (TKIs) that specifically target EGFR in the treatment of NSCLC have been developed.

Gefitinib, the first small molecule inhibitor of EGFR, was found to significantly prolong progression-free survival (PFS) in a subset of patients with advanced NSCLC. Subsequent findings showed that these patients had activating somatic mutations in the *EGFR* gene \[[@b5-crt-2014-362],[@b6-crt-2014-362]\]. In an analysis of several studies involving treatment with the EGFR-targeted TKIs, gefitinib and erlotinib, resulted in a response to therapy in approximately 68% and 11% of patients who tested positive and negative (hereafter referred to as EGFR-positive and EGFR-negative) for activating *EGFR* mutations, respectively \[[@b4-crt-2014-362]\]. Correlation between *EGFR* mutations and enhanced response to TKI therapy has been verified by a number of randomized trials \[[@b7-crt-2014-362]-[@b13-crt-2014-362]\] including the Iressa Pan Asia Study (IPASS). In general, patients harboring *EGFR* mutations have a longer PFS with EGFR TKI therapy compared to chemotherapy, and show a more favorable response to EGFR TKI therapy than patients without *EGFR* mutations. Therefore, given that more than half of patients with NSCLC in East Asia who are non-smokers and have adenocarcinoma histology harbor *EGFR* mutations \[[@b14-crt-2014-362]\], it has become common practice in some Asian countries (where *EGFR* mutation testing is readily available and/or subsidized) to treat patients based on their EGFR status. Yet, in some clinical practices, this subgroup of patients is still treated with TKIs without prior testing for EGFR status because physicians are reluctant to delay the start of treatment or because sufficient tumor tissue may not be available. However, as noted above, EGFR-negative patients do not respond as well to TKI therapy as they do to standard chemotherapy, and, therefore, have inferior outcomes; thus, this may not be the best practice \[[@b13-crt-2014-362]\].

Body Text
=========

Here we report on experience gained from a series of studies conducted predominantly in East Asia and highlight some of the key findings and major limitations associated with determining EGFR status in patients with non-squamous NSCLC. The value of *EGFR* mutation status in predicting treatment outcomes was examined in a series of studies on East Asian patients with advanced NSCLC, in which the effect of EGFR TKI therapy, alone or in combination with standard chemotherapy, on treatment outcomes was examined in EGFR-positive and EGFR-negative patient subgroups ([Table 1](#t1-crt-2014-362){ref-type="table"}, [Figs. 1](#f1-crt-2014-362){ref-type="fig"} and [2](#f2-crt-2014-362){ref-type="fig"}) \[[@b15-crt-2014-362]-[@b17-crt-2014-362]\]. In a phase 2 randomized controlled trial involving 240 non-smoking patients with non-squamous NSCLC, of which 133 were East Asian, pemetrexed and erlotinib in combination were compared to either agent alone in the second-line treatment setting \[[@b15-crt-2014-362]\]. Collection of samples for EGFR testing was optional. As a result, in the East Asian population, EGFR status was available for only 31 patients, 19 of whom (61%) were EGFR positive, as expected by the clinical selection criteria. In these EGFR-positive patients from East Asia, patients treated with erlotinib had longer PFS than those treated with pemetrexed ([Table 1](#t1-crt-2014-362){ref-type="table"}, [Fig. 1A](#f1-crt-2014-362){ref-type="fig"}) \[[@b15-crt-2014-362]\]. In contrast, in EGFR-negative patients, PFS was generally longer in patients treated with erlotinib in combination with pemetrexed than in those treated with either agent alone ([Table 1](#t1-crt-2014-362){ref-type="table"}, [Fig. 1A](#f1-crt-2014-362){ref-type="fig"}) \[[@b15-crt-2014-362]\]. No obvious difference in change in lesion sum from baseline at best response was observed between treatment arms ([Fig. 1B](#f1-crt-2014-362){ref-type="fig"}).

In a subsequent, open-label, phase 3 randomized trial involving 236 never-smoker East Asian patients with NSCLC, pemetrexed-cisplatin doublet chemotherapy as first-line treatment followed by gefitinib maintenance therapy was compared to gefitinib monotherapy \[[@b16-crt-2014-362]\]. Again, tissue collection for EGFR status was recommended but not mandatory, and the majority of tissue biopsies provided were too small for EGFR analysis. As a result, EGFR status was available for only 74 patients, 50 of whom (68%) were EGFR-positive. In EGFR-positive patients, there was no difference in PFS between treatment arms ([Table 1](#t1-crt-2014-362){ref-type="table"}, [Fig. 2A](#f2-crt-2014-362){ref-type="fig"}) \[[@b16-crt-2014-362]\]. However, in EGFR-negative patients, patients receiving gefitinib monotherapy had shorter PFS compared to patients receiving chemotherapy followed by gefitinib maintenance ([Fig. 2A](#f2-crt-2014-362){ref-type="fig"}) \[[@b16-crt-2014-362]\]. The beneficial effect of chemotherapy followed by gefitinib maintenance therapy in EGFR-negative patients was further evident by a reduction in the lesion sum from baseline at best response in these patients compared with patients receiving gefitinib monotherapy, in whom the lesion sum increased ([Fig. 2B](#f2-crt-2014-362){ref-type="fig"}). These studies identified *EGFR* mutation status as a key predictor of outcome in East Asian never-smoker patients with non-squamous NSCLC and further confirmed that treating East Asian patients with NSCLC with EGFR TKIs is not necessarily beneficial in the absence of *EGFR* mutations \[[@b13-crt-2014-362],[@b15-crt-2014-362]-[@b18-crt-2014-362]\]. Therefore, the findings from these studies highlight the potential benefits of consistent testing for EGFR status before determining the optimal treatment regimen for patients with NSCLC.

Testing for EGFR status is primarily restricted by challenges in specimen collection. In the phase 2 study by Lee et al. \[[@b15-crt-2014-362]\], fewer than 25% of patients provided samples for EGFR testing, approximately 20% of which were not evaluable. In the phase 3 study by Yang et al. \[[@b16-crt-2014-362]\] conducted 2 years later, when there was an increased awareness of the need for EGFR testing, a greater proportion (60%) of patients provided samples. However, almost 50% of these samples were not evaluable. Although there was an increased awareness of the importance of EGFR testing during the phase 3 study \[[@b16-crt-2014-362]\], the frequency of testing could still be improved to allow more patients to benefit from the most appropriately selected treatment. Due to the invasive nature of obtaining tissue biopsies, the limited availability of tissue for testing continues to hinder progress. In addition, greater efforts in sampling can be made to improve the proportion of evaluable samples. In cases where tissue samples are available, further care is needed in obtaining good-quality samples at the time of the first diagnostic biopsy and in preparation, storage, and testing of the samples.

Conclusion
==========

Based on the findings of the studies discussed above, it has become evident that physicians should test for *EGFR* mutation status, even in patients from East Asia, before deciding on the most appropriate treatment for patients with NSCLC. This is important because the treatment regimen cannot be optimized for patients with unknown EGFR status, which could compromise patient outcomes. In the phase 2 and phase 3 studies discussed here \[[@b15-crt-2014-362],[@b16-crt-2014-362]\], EGFR status was tested retrospectively. Only a few patients provided samples and among those who did, even fewer samples yielded results. Thus, very low numbers were available to validate the clinical outcomes and enable accurate interpretation of the study findings. Molecular testing of biopsy samples for EGFR status is now being performed more frequently in clinical practice. However, still fewer than half of patients are providing samples and the sample quality may not be ideal for molecular testing. In light of the clinically relevant differences in response to TKI therapy and chemotherapy in patients with NSCLC who are EGFR-positive and EGFR-negative \[[@b13-crt-2014-362],[@b15-crt-2014-362]-[@b17-crt-2014-362]\], patients should be tested for EGFR status before deciding on the most effective treatment regimen. Biomarker testing is becoming more important in clinical practice. Key challenges that investigators will need to overcome in the future include obtaining sufficient tumor tissue and development of more sensitive and more robust methods for testing.
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###### 

Efficacy analysis of patients with non-small cell lung cancer based on epidermal growth factor receptor status (from Yang et al. \[[@b16-crt-2014-362]\] and unpublished data from Lee et al. \[[@b17-crt-2014-362]\])

  Variable                                                  Lee et al. \[[@b17-crt-2014-362]\]   Yang et al. \[[@b16-crt-2014-362]\]                                                                                   
  --------------------------------------------------------- ------------------------------------ ------------------------------------- ---------- ---------- ---------- ---------- ----------- ----------- ----------- ----------
  PFS                                                                                                                                                                                                                  
   Median (mo)                                              7.4                                  12.9                                  3.0        5.7        2.3        1.4        12.9        16.6        9.9         1.4
   p-value[^a)^](#tfn1-crt-2014-362){ref-type="table-fn"}   ND                                                                                    ND                               0.585                   0.001       
  Response rate                                                                                                                                                                                                        
   TRR[^b)^](#tfn2-crt-2014-362){ref-type="table-fn"}                                                                                                                                                                  
    No. (%)                                                 4 (80.0)                             5 (62.5)                              0          3 (60.0)   0          1 (33.3)   17 (65.4)   17 (70.8)   3 (23.1)    0
    p-value                                                 0.017                                                                                 0.253                            0.767                   0.223       
   DCR[^c)^](#tfn3-crt-2014-362){ref-type="table-fn"}                                                                                                                                                                  
    No. (%)                                                 5 (100.0)                            7 (87.5)                              2 (33.3)   3 (60.0)   2 (50.0)   1 (33.3)   22 (84.6)   21 (87.5)   10 (76.9)   2 (18.2)
    p-value                                                 0.028                                                                                 1.000                            1.000                   0.012       

EGFR, epidermal growth factor receptor; PE, pemetrexed-erlotinib; E, erlotinib; P, pemetrexted; PC/G, pemetrexed-cisplatin/gefitinib; G, gefitinib; PFS, progression-free survival; ND, not determined; TRR, tumor response rate; DCR, disease control rate. p-values derived from Wilcoxon test for PFS and Fisher exact test for TRR and DCR.

p-values for PFS were not determined in Lee et al. \[[@b17-crt-2014-362]\] because the number of patients in each group was too low,

TRR=complete response+partial response,

DCR=complete response+partial response+stable disease.
